Effect of multi-modal interventions for smoking cessation in a university setting: A short course of varenicline, financial incentives, e-mail and short message service

Korean Journal of Family Medicine

Volumn 31, Issue 5, 2010, Pages 355-360

  Cheong, Yoo Seock ^a   Ahn, Sang Hyun ^b  

^a Dankook University College of Medicine   (South Korea)

^b Asan Public Health Center   (South Korea)

Author keywords

Multimodal intervention; Smoiking cessation; Varenicline

Indexed keywords

EID: 80052919883     PISSN: 20056443     EISSN: 20926715     Source Type: Journal    
DOI: 10.4082/kjfm.2010.31.5.355     Document Type: Article

References (15)

1. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009;14:384-92.
2. Park SE, Song HR, Kim CH, Ko SK. Economic burden of smoking in Korea, 2007. Korean J Health Promot Dis Prev 2008;8:219-27.
3. Korean Statistical Information Service [Internet]. Daejeon: Korean Statistical Information Service; c2009 [cited 2009 Jun 20]. Available from: http://www.kosis.kr.
4. Ramon JM, Bruguera E. Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Int J Environ Res Public Health 2009;6:1530-8.
5. McEwen A, West R, McRobbie H. Effectiveness of specialist group treatment for smoking cessation vs. one-to-one treatment in primary care. Addict Behav 2006;31:1650-60.
6. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009;31:463-91.
7. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
8. Lee JH, Jones PG, Bybee K, O'Keefe JH. A longer course of varenicline therapy improves smoking cessation rates. Prev Cardiol 2008;11:210-4.
9. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56.
10. TsaiST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39.
11. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009;360:699-709.
12. Brendryen H, Kraft P. Happy ending: a randomized controlled trial of a digital multi-media smoking cessation intervention. Addiction 2008;103:478-84.
13. Park SM, Son KY, Lee YJ, Lee HC, Kang JH, Lee YJ, et al. A preliminary investigation of early smoking initiation and nicotine dependence in Korean adults. Drug Alcohol Depend 2004;74:197-203.
14. Hotta K, Kinumi K, Naito K, Kuroki K, Sakane H, Imai A, et al. An intensive group therapy programme for smoking cessation using nicotine patch and internet mailing supports in a university setting. Int J Clin Pract 2007;61:1997-2001.
15. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: resultsfrom a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8.